Research programme: HIV tat inhibitors - AmgenAlternative Names: HIV tat inhibitors research programme - Amgen
Latest Information Update: 09 Dec 2003
At a glance
- Originator Tularik
- Class Small molecules
- Mechanism of Action HIV replication inhibitors; Human immunodeficiency virus tat gene product inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 09 Dec 2003 Discontinued - Preclinical for HIV infections treatment in USA (PO)
- 10 Mar 1999 Preclinical development for HIV infections treatment in USA (PO)